The spatiotemporal distribution of substandard and falsified antimalarial medicines in Africa, 1996-2019
This study utilizes spatiotemporal modeling of data from 1996 to 2019 to estimate that substandard and falsified antimalarial prevalence in Africa was highest between 1996 and 2003, particularly in West and Central regions, while showing a notable decline in several East African countries and Madagascar after 2003, though findings remain uncertain due to sparse surveillance data.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Malaria remains one of the most persistent threats to human health, particularly across the African continent, where the vast majority of global cases and deaths occur. The fight against this disease relies heavily on medicines that work exactly as intended. However, the global supply chain is not immune to failure or fraud. Some medicines are substandard, meaning they were made by legitimate manufacturers but failed to meet quality standards due to poor storage, expired ingredients, or manufacturing errors. Others are falsified, deliberately created to look like real medicine but containing the wrong ingredients, the wrong amount of medicine, or no medicine at all. When patients take these ineffective drugs, the illness lingers, the risk of death increases, and the parasite can develop resistance to the very treatments meant to cure it. Understanding where and when these bad medicines appear is the first step toward stopping them, yet for a long time, the picture of this problem across Africa has been fragmented and unclear.
A team of researchers set out to map this hidden landscape by gathering every available piece of data on antimalarial quality from 1996 to 2019. They pulled information from 76 different surveys conducted across 27 African countries, analyzing a total of 8,213 medicine samples. These surveys came from a mix of sources, including some that randomly selected shops and others that simply collected whatever was available nearby. The researchers found that the quality of the data varied significantly; samples collected through random, systematic methods showed a lower rate of bad medicine, while those gathered through convenience methods often revealed higher rates of failure. In total, about 22 percent of all the samples tested were either substandard or falsified. The study also highlighted that the type of medicine mattered. While common treatments like artemether-lumefantrine and quinine made up the bulk of the samples, other specific combinations, such as those containing artesunate and sulphadoxine-pyrimethamine, showed alarmingly high failure rates in the limited tests available.
To turn these scattered data points into a clear picture, the researchers used a sophisticated statistical approach that allowed them to estimate the prevalence of bad medicines for every year and every country in their study, even where no direct testing had occurred. They built three different models to see which one best explained the patterns they observed, comparing how well each could predict the data they already had. The model that performed best included a way to account for how conditions in neighboring countries might influence one another and how trends changed over time. This approach suggested that the highest prevalence of substandard and falsified antimalarials occurred between 1996 and 2003, with the problem being particularly concentrated in West and Central Africa.
The study also revealed that the situation was not static; it changed over time. While many countries showed no clear pattern of improvement or decline, the researchers estimated a notable drop in the proportion of bad medicines in Kenya, Uganda, Tanzania, and Madagascar starting around 2003. This suggests that interventions in these specific nations may have begun to take effect. However, the researchers were careful to note that their findings come with significant uncertainty. Because the underlying data is sparse, with many countries having only one or two surveys over the entire 24-year period, the estimates for many places are broad guesses rather than precise measurements. The maps they produced show the likely range of where the problem exists, but they also highlight the vast gaps in surveillance. The work serves as a crucial guide, pointing out where the problem is most severe and where the lack of data itself is a danger, urging regulators and health officials to focus their efforts on strengthening systems and filling in the blind spots across the continent.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.